网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
吡格列酮对肥胖2型糖尿病患者炎症因子的影响
作者:朱亭 邓月珍 叶飞  
单位:扬州大学附属泰兴市人民医院
关键词:2型糖尿病 吡格列酮 炎症 
分类号:
出版年·卷·期(页码):2013·41·第一期(23-25)
摘要:

目的 探讨吡格列酮(PGZ)对肥胖2型糖尿病(T2DM)患者炎症因子C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及单核细胞趋化蛋白-1(MCP-1)的影响。方法 将69例肥胖T2DM患者用随机双盲法分为PGZ组和常规组,另选取50例健康人作为对照,治疗前后分别用ELISA法检测患者血清CRP、TNF-α、IL-6、MCP-1水平。结果 与正常对照组比较,肥胖T2DM组血清CRP、TNF-α、IL-6、MCP-1水平显著升高(P0.05)。结论PGZ能降低肥胖T2DM患者血清炎症因子水平,具有抗炎作用。

Objective To investigate the effects of PGZ on inflammatory factors in obesity patients with T2DM.Methods A case-control and a self-controlled study were conducted in 69 obesity patients with T2DM and 50 healthy subjects.Serum inflammatory factors such as CRP,TNF-α,IL-6 and MCP-1 were compared between the two groups,and the changes were measured after treatment with PGZ for 12 weeks.Results Compared with healthy group,obesity patients with T2DM have a notable high levels of inflammatory factors, after treatment with PGZ, the levels decreased significantly. Conclusion PGZ can decrease the levels of inflammatory factors in obesity patients with T2DM.

参考文献:
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 758540 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541